Detalhe da pesquisa
1.
Targeting of intracellular oncoproteins with peptide-centric CARs.
Nature
; 623(7988): 820-827, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37938771
2.
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Nature
; 599(7885): 477-484, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732890
3.
Epigenetic state determines inflammatory sensing in neuroblastoma.
Proc Natl Acad Sci U S A
; 119(6)2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121657
4.
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Nature
; 623(7988): 872, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37938785
5.
Genetic susceptibility to neuroblastoma: current knowledge and future directions.
Cell Tissue Res
; 372(2): 287-307, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29589100
6.
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Cancer
; 122(1): 20-33, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26539795
7.
Correction to: Genetic susceptibility to neuroblastoma: current knowledge and future directions.
Cell Tissue Res
; 383(2): 905, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32897422
8.
BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
J Natl Cancer Inst
; 116(1): 138-148, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688570
9.
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.
J Natl Cancer Inst
; 116(1): 149-159, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688579
10.
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
bioRxiv
; 2024 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106022
11.
BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
bioRxiv
; 2023 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36778420
12.
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma.
Sci Adv
; 9(34): eadg6693, 2023 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611092
13.
Germline pathogenic variants in 786 neuroblastoma patients.
medRxiv
; 2023 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36747619
14.
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
J Immunother Cancer
; 10(12)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460335
15.
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Cancer Discov
; 12(12): 2800-2819, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108156
16.
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
J Immunother Cancer
; 10(9)2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36167467
17.
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Cancer Cell
; 40(1): 53-69.e9, 2022 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34971569
18.
Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Mol Cancer Ther
; 20(11): 2228-2239, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465595
19.
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Cell Rep Med
; 2(7): 100344, 2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34337560
20.
Suspected posaconazole toxicity in a pediatric oncology patient.
Pediatr Blood Cancer
; 62(9): 1682, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25950873